CD4-IgG2 formulations

/Home/Lyophilization and Protein Formulation Patents/Patent Articles - Lyophilization/Patent Pending - Lyophilization

CD4-IgG2 formulations
Engineering Village
Publication number: US20050142139

Application number: 804802

Unstandardized application number: 10804802

Patent authority: US

Kind: A1 - Utility Patent Application

Title: CD4-IgG2 formulations

Inventors: Isaacs, Indu (US) ; Parkhurst-Lang, Cherie (US) ; Olson, William C. (US) ; Schulke, Norbert (US)

Publication date: 06/30/2005

Publication year: 2005

Filing date: 03/19/2004

Abstract: This invention provides formulations of the anti-HIV therapeutic, CD4-IgG2, that contain higher concentrations of the therapeutic than were previously prepared, are stable, compatible with lyophilization, and safe to administer. These formulations are suitable for intravenous, subcutaneous and intramuscular delivery, the latter two routes being potentially useful for facilitating self-administration by HIV-infected individuals. This invention is also directed to methods of making the CD4-IgG2 formulations described in the disclosure, and methods of using the formulations to inhibit or prevent infect CD4+ cells from becoming infected with HIV, and to treat subjects having CD4+ cells infected with HIV.

Document type: US Application

IPC Code: A61K39/395 SECTION A HUMAN NECESSITIES
MEDICAL OR VETERINARY SCIENCE; HYGIENE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES bringing into special physical form ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; compounds per se , , , ; soap compositions ; micro-organisms per se
Medicinal preparations containing antigens or antibodies materials for immunoassay 2
Antibodies agglutinins ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum 3

A61K31/417.2 No data available

US Classification: 514/400 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
Chalcogen bonded directly to carbon of the hetero ring of the quinoline ring system
Having -C(=X)-, wherein X is chalcogen, bonded directly to carbon of the hetero ring of the quinoline ring system
Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)
1,3-diazoles
Imidazoles
Chalcogen or nitrogen bonded indirectly to the imidazole ring by nonionic bonding
At imidazole ring carbon

424/178.1 DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS
CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL

Database: US Patents

Compilation and indexing terms, ? 2006 LexisNexis Univentio B.V.
This is a subscription site. You will need to subscribe to Engineering Village 2 to view the details.